×

SAGE Therapeutics Announces Six Scientific Presentations at Neuroscience 2014, the Society for Neuroscience's 44th Annual Meeting

CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that six abstracts have been accepted for poster presentations at Neuroscience 2014, the Society for Neuroscience's 44th Annual Meeting. The meeting will take place from November 15-19 at the Walter E. Washington Convention Center in Washington, DC.

Following is a schedule of SAGE's poster presentations:

Saturday, Nov. 15

Time: 4:00 PM - 5:00 PM
Location: WCC Hall A-C
Title: Pharmacological characterization of novel neuroactive steroid modulators of NMDA receptors

Sunday, Nov. 16

Time: 8:00 AM - 9:00 AM
Location: WCC Hall A-C
Title: A pharmacological characterization of novel neuroactive steroid modulators of GABAA receptors

Tuesday, Nov. 18

Time: 11:00 AM - 12:00 PM
Location: WCC Hall A-C
Title: Distributed kinetic effects of oxysterol positive modulators on NMDA channels

Wednesday, Nov. 19

Time: 8:00 AM - 9:00 AM
Location: WCC Hall A-C
Title: Allopregnanolone preclinical therapeutic development in relevant aging and Alzheimer's disease models

Time: 8:00 AM - 9:00 AM
Location: WCC Hall A-C
Title: A novel GABAA receptor positive allosteric modulator preferentially enhances extrasynaptic GABAA receptors and rescues deficient tonic GABAergic currents in a mouse model of Fragile-X Syndrome

Time: 10:00 AM - 11:00 AM
Location: WCC Hall A-C
Title: A new method for determining the degree of sedation in beagle dogs; validation with propofol and comparison to a novel compound

About SAGE Therapeutics

SAGE Therapeutics (Nasdaq:SAGE) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus, or SRSE, and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit www.sagerx.com.

Forward-Looking Statements

This release contains forward-looking statements and information, including statements concerning SAGE's expectations regarding the potential safety, pharmacological effect and efficacy of SAGE-547, the expected development pathway for SAGE-547 and other product candidates and its expectations with respect to the timing and success of its clinical trials concerning its product candidates, and the applicability of the results from emergency-use cases to the population at large. These and other statements concerning SAGE's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In particular it should be noted that the initial data reported from the ongoing Phase 1/2 clinical trial of SAGE-547 are preliminary in nature and that the SAGE-547 clinical trial has not been completed. The preliminary data may change as additional data is released and such preliminary data may not be repeated or observed in ongoing or future studies involving SAGE-547 or SAGE's other product candidates. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, SAGE's ability to successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, SAGE's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, SAGE's ability to manage operating expenses, SAGE's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, SAGE's dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as discussions of potential risks, uncertainties, and other important factors in SAGE's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent SAGE's views only as of today and should not be relied upon as representing its views as of any subsequent date. SAGE explicitly disclaims any obligation to update any forward-looking statements.

CONTACT: Media Contact: Dan Budwick, Pure Communications dan@purecommunicationsinc.com 973-271-6085 Investor Contact: Monique Allaire Lyons, Pure Communications monique@purecommunicationsinc.com 781-631-0759

Source:SAGE Therapeutics